

BEYOND STATINS: ADVANCES IN CVD RISK REDUCTION



The Post MI Patient:

A GP's practical guide to lipid lowering, PCSK9 inhibition and Repatha® (evolocumab)

INVITATION

Speaker	Prof. Christian Hamilton-Craig Cardiologist & Cardiac Imaging Specialist - Sunshine Coast
Date	Wednesday 23 Nov, 2022. 6:45pm - 9:15pm
Venue	Spirit House Restaurant 20 Ninderry Rd, Yandina

GP INITIATION OF REPATHA® IS COMING SOON!

The PBAC recently recommended GP initiation of Repatha®, in consultation with a specialist physician - *update to the PBS listing is pending.*¹

Attend a meeting to prepare for the PBS listing change, enabling you to add Repatha® to your suite of lipid-lowering therapies.

Meeting objectives include:

- Refresh on managing high-risk atherosclerotic cardiovascular disease (ASCVD) patients
- Revisit the importance of treating lipids to target for CV risk reduction
- Learn about Repatha® – indications, safety, efficacy, dosing and administration
- Understand how to access Repatha® on the PBS

Register at:
amgen.cventevents.com/beyondstatins2022

If you cannot attend the meeting above, you will find options for other meetings, local to you, via this link / QR code.

*Please note that only hospitality is provided.
Travel or accommodation is not covered.*



AGENDA

6:45pm	REGISTRATION
7:00pm	MEAL SERVICE
7:15pm	WELCOME AND INTRODUCTION
7:30pm	BEYOND STATINS: ADVANCES IN CVD RISK REDUCTION – THE POST-MI PATIENT AND MAIN MEAL SERVICE
8:30pm	Q&A DISCUSSION
9:00pm	SUMMARY AND CLOSE
9:15pm	CLOSE

FOR FURTHER INFORMATION CONTACT YOUR AMGEN REPRESENTATIVE

NAME: **Paul Bridgman**

EMAIL: **pbridgma@amgen.com**

PHONE: **0448 674 266**

AMGEN[®]

Cardiovascular

PBS Information: Authority Required. Non-familial and familial hypercholesterolaemia. Criteria apply for certain patient populations. **Refer to PBS Schedule for full Authority Required information. Refer to full Product Information before prescribing; available from Amgen Australia Pty Ltd, Ph: 1800 803 638 or at www.amgen.com.au/Repatha.PI.** For more information on Repatha[®] or to report an adverse event or product complaint involving Repatha[®], please contact Amgen Medical Information on 1800 803 638 or visit www.amgenmedinfo.com.au.

SCAN QR CODE
to see full Repatha[®]
Product Information



Abbreviations: CV = cardiovascular; CVD = cardiovascular disease; MI = myocardial infarct; PBAC = Pharmaceutical Benefits Advisory Committee; PBS = Pharmaceutical Benefits Scheme; PCSK9 = proprotein convertase subtilisin/kexin type 9. **References:** 1. Pharmaceutical Benefits Scheme. Recommendations made by the Pharmaceutical Benefits Advisory Committee – July 2022. Available at: <https://www.pbs.gov.au/info/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-made-by-the-pbac-july-2022>.

Privacy Statement: Amgen Australia collects your personal information to enable us to manage and promote our educational events and educational events convened by other organisations, follow up with you about your experience at these events and engage with you for the purpose of our promotional activities. For this purpose, we may disclose your personal information to Amgen Australia's related entities, as well as to trusted third parties and suppliers who assist us in providing our products and services, and market research agencies. These related entities and third parties may be located in other countries including the United States of America and in Europe and Asia. Amgen Australia remains accountable for all personal information it discloses and takes appropriate measures to ensure that the confidentiality of your information is safeguarded. For more information on privacy at Amgen, including how you may access or correct your personal information or make a privacy complaint, please see our privacy policy available at www.amgen.com.au/privacy-statement/ or contact our Privacy Officer at: Attn: Privacy Officer, Amgen Australia Pty Ltd, Level 11, 10 Carrington St, Sydney, NSW 2000 Email: privacyoffice@amgen.com Tel: +61 2 9870 1333. Amgen Australia Pty Ltd. ABN 31 051 057 428, Sydney NSW 2000. ©2022 Amgen Inc. All rights reserved. AU-17641 RGP0009. Date of preparation: October 2022.